Search
MD, PhD, Prof Wojciech Jurczak
Employment
Research fields
- No data
Publications
Filters
total: 53
Catalog Publications
Year 2018
-
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
Publication -
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma
Publication -
Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma
Publication -
Efficacy and safety of the obinutuzumab-chlorambucil combination in the frontline treatment of elderly CLL patients with comorbidities – Polish Adult Leukemia Group (PALG) real-life analysis
Publication -
Hodgkin lymphoma of the elderly patients: a retrospective multicenter analysis from the Polish Lymphoma Research Group
Publication -
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study
Publication -
Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study
Publication -
Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia
Publication -
Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma
Publication -
Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy
Publication -
Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma
Publication -
Use of acalabrutinib in patients with mantle cell lymphoma
Publication -
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial
Publication
Year 2017
-
Acute decompensated heart failure as a reason of premature chemotherapy discontinuation may be independent of a lifetime doxorubicin dose in lymphoma patients with cardiovascular disorders
Publication -
Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study
Publication -
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial
Publication -
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus
Publication -
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
Publication -
Research on Biosimilars: pivotal trials and principles
Publication -
Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study
Publication -
Rytuksymab – pierwsze biopodobne przeciwciała monoklonalne w hematoonkologii
Publication
Year 2016
-
Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent <i>CARD11</i> mutations
Publication -
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
Publication -
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial
Publication -
Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma
Publication -
Postibrutinib outcomes in patients with mantle cell lymphoma
Publication -
Primary mediastinal B-cell lymphoma – metabolic and anatomical features in 18FDG-PET/CT and response to therapy
Publication -
Single-agent MOR208 salvage and maintenance therapy in a patient with refractory/relapsing diffuse large B-cell lymphoma: a case report
Publication -
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
Publication
Year 2015
-
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
Publication -
Gemcitabine-Based Treatment in Poor Prognosis Patients with Relapsed and Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma – a Multicenter Polish Experience
Publication -
Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers
Publication -
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
Publication -
Multicentre, Prospective Observational Study of Pegfilgrastim Primary Prophylaxis in Patients at High Risk of Febrile Neutropenia in Poland: PROFIL Study
Publication -
Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group
Publication -
The use of Yttrium-90 Ibritumomab Tiuxetan ( 90 Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation
Publication
Year 2014
-
Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report
Publication -
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Publication -
Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma
Publication -
Skuteczność liposomalnej cytarabiny w leczeniu pierwotnego i wtórnego zajęcia ośrodkowego układu nerwowego w przebiegu chłoniaków nieziarniczych – ocena retrospektywna pacjentów leczonych w Klinice Hematologii UJ CM
Publication
Year 2013
-
Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network†
Publication -
Central nervous system prophylaxis with intrathecal liposomal cytarabine in diffuse large B‑cell lymphomas
Publication -
Inhibitor kinazy Brutona u chorych z nawrotowym lub opornym na leczenie chłoniakiem z komórek płaszcza – wyniki międzynarodowego, wieloośrodkowego, badania II fazy z ibrutynibem (PCI-32765) – EHA Encore
Publication -
Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen — A national multicenter study
Publication -
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Publication
Year 2012
Year 2011
-
Radioimmunotherapy Confers Long-Term Survival to Lymphoma Patients with Acceptable Toxicity: Registry Analysis by the International Radioimmunotherapy Network
Publication -
Radioimmunotherapy with 90Y-ibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: an analysis of the international RIT-Network
Publication
Year 2010
Year 2008
seen 849 times